|
1
|
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
|
J Clin Oncol
|
2001
|
3.06
|
|
2
|
Survival among women with triple receptor-negative breast cancer and brain metastases.
|
Ann Oncol
|
2009
|
2.21
|
|
3
|
Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
|
Ann Oncol
|
2008
|
2.12
|
|
4
|
Trastuzumab: triumphs and tribulations.
|
Oncogene
|
2007
|
1.94
|
|
5
|
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
|
Ann Oncol
|
2011
|
1.45
|
|
6
|
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
|
Ann Oncol
|
2008
|
1.07
|
|
7
|
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer.
|
Ann Oncol
|
2007
|
0.97
|
|
8
|
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy.
|
J Clin Oncol
|
2001
|
0.93
|
|
9
|
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
|
J Clin Oncol
|
2001
|
0.92
|
|
10
|
Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
|
Br J Cancer
|
2013
|
0.90
|
|
11
|
Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer.
|
Oncogene
|
2009
|
0.89
|
|
12
|
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
|
J Clin Oncol
|
2001
|
0.88
|
|
13
|
Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
|
Semin Oncol
|
2000
|
0.86
|
|
14
|
Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer.
|
Ann Oncol
|
2012
|
0.83
|
|
15
|
Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response.
|
Breast Dis
|
2000
|
0.82
|
|
16
|
Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.
|
Cancer Treat Rev
|
1999
|
0.81
|
|
17
|
Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug?
|
Oncologist
|
2001
|
0.75
|